Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Long-term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase 2 Results from Double-blind and Open-Label Extension Studies.
Journal: The Journal of rheumatology
Published: August 01, 2026
Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.
Journal: Clinical, cosmetic and investigational dermatology
Published: January 07, 2026
Unlocking disease insights to facilitate drug development: Pharmaceutical industry-academia collaborations in inflammation and immunology.
Journal: Drug discovery today
Published: October 31, 2024
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Journal: Lancet (London, England)
Published: February 22, 2024
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: December 21, 2023
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Journal: Modern rheumatology
Published: April 13, 2022
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Journal: Arthritis research & therapy
Published: May 14, 2021
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
Journal: RMD open
Published: March 16, 2021
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
Journal: RMD open
Published: February 12, 2021
Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Journal: Modern rheumatology
Published: June 15, 2019
Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
Journal: Modern rheumatology
Published: May 25, 2018
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Journal: Annals of the rheumatic diseases
Published: April 11, 2017
Last Updated: 09/26/2026